多剤耐性菌の世界市場レポート 2025年

多剤耐性菌市場規模は、今後数年間で力強い成長が見込まれます。2029年には175億米ドルに成長し、CAGRは6.9％となります。予測期間の成長は、抗生物質スチュワードシップ・プログラム、世界の耐性菌の蔓延、ファージ療法と代替治療、公共投資と民間投資に起因すると考えられます。予測期間の世界の動向には、感染症の精密医療、併用療法、継続的な監視とモニタリング、世界の協力体制などが含まれます。

感染症の蔓延拡大は、多剤耐性菌市場の拡大を促進すると予想されます。感染症は、細菌、ウイルス、真菌、寄生虫などの有害な微生物によって引き起こされる病気です。多剤耐性菌は、標準的な抗生物質では治療が困難な感染症を引き起こす能力を持っているため、特に感染症に関連しています。これらの細菌は複数の抗生物質に対する耐性を獲得しており、細菌感染症の治療に通常使用される薬剤に反応しにくくなっています。例えば、2023年11月、米国を拠点とする国立公衆衛生機関である疾病対策予防センター（CDC）は、米国における結核患者数が2022年の8,320人から2023年には9,615人に増加し、1,295人の増加を反映したと報告しました。したがって、感染症の流行が増加していることが、多剤耐性菌市場の成長を促進すると予想されます。

多剤耐性菌市場で事業を展開する主要企業は、新たな消費者層のニーズに対応するため、革新的な医薬品の開発と承認取得に力を入れています。多剤耐性菌に対抗するために設計された薬剤の承認は、抗生物質耐性との継続的な戦いにおいて極めて重要です。例えば、米国のバイオテクノロジー企業であるエンタシス・セラピューティクス社は、2023年5月、治療が特に困難な病原体であるアシネトバクター・バウマニによる院内細菌性肺炎（HABP）および人工呼吸器関連細菌性肺炎（VAP）を治療するために配合された抗生物質製剤であるザクデュオールについて、食品医薬品局（FDA）から承認を取得しました。Xacduorは、セフトロザンとリン酸テジゾリドの配合剤です。セフトロザンはセファロスポリン系抗生物質で、リン酸テジゾリドはオキサゾリジノンクラスの抗生物質に属します。今回の承認は、他の治療法に反応しないアシネトバクター・バウマンニ感染患者に新たな治療選択肢を提供するものです。本剤は注射により投与され、抗生物質β-ラクタム系スルバクタムと広域β-ラクタマーゼ阻害剤デュロバクタムを併用することで、アシネトバクター耐性を低下させ、感染症に効果的に対処することができます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界多剤耐性菌PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の多剤耐性菌市場：成長率分析
• 世界の多剤耐性菌市場の実績：規模と成長, 2019-2024
• 世界の多剤耐性菌市場の予測：規模と成長, 2024-2029, 2034F
• 世界多剤耐性菌総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の多剤耐性菌市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 尿路感染症
• 腹腔内感染症
• 血流感染症
• クロストリジウム・ディフィシル感染症
• 急性細菌性皮膚および皮膚構造感染症
• 院内細菌性肺炎
• 後天性細菌性肺炎
• その他の病気
• 世界の多剤耐性菌市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オキサゾリジノン
• リポグリコペプチド
• テトラサイクリン
• セファロスポリン
• 併用療法
• その他の薬物クラス
• 世界の多剤耐性菌市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の多剤耐性菌市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の多剤耐性菌市場尿路感染症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 膀胱炎
• 腎盂腎炎
• 世界の多剤耐性菌市場腹腔内感染症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 虫垂炎
• 腹膜炎
• 世界の多剤耐性菌市場、血流感染症の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 菌血症
• 敗血症
• 世界の多剤耐性菌市場、クロストリジウム・ディフィシル感染症の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽度のCDI
• 重度のCDI
• 世界の多剤耐性菌市場急性細菌性皮膚および皮膚構造感染症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 蜂窩織炎
• 膿瘍
• 世界の多剤耐性菌市場院内細菌性肺炎の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 人工呼吸器関連肺炎
• 院内肺炎
• 世界の多剤耐性菌市場、後天性細菌性肺炎の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 市中肺炎
• 誤嚥性肺炎
• 世界の多剤耐性菌市場、その他の疾患のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 骨と関節の感染症
• 心内膜炎

第7章 地域別・国別分析

• 世界の多剤耐性菌市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の多剤耐性菌市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多剤耐性菌市場：競合情勢
• 多剤耐性菌市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson And Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Dr. Reddy's Laboratories Ltd.
• Lupin Pharmaceuticals Inc.
• BioMarin Pharmaceuticals Inc.
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 多剤耐性菌市場2029：新たな機会を提供する国
• 多剤耐性菌市場2029：新たな機会を提供するセグメント
• 多剤耐性菌市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Multidrug-resistant bacteria are strains of bacteria that have developed resistance to multiple classes of antibiotics, rendering them no longer susceptible to the effects of several different antibiotics that are typically effective in treating bacterial infections. These resilient bacteria are often found in hospital and medical care settings, where antibiotics are sometimes overused or used unnecessarily.

Various diseases are caused by multidrug-resistant bacteria, including urinary tract infections, intra-abdominal infections, bloodstream infections, Clostridium difficile infections, acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia, among others. Urinary tract infections, for example, can affect different parts of the urinary system, such as the kidneys, bladder, and ureters. The treatment of these diseases involves the use of various drugs, including oxyazolidinones, lipoglycopeptides, tetracyclines, cephalosporins, combination therapies, and more, administered through oral, parenteral, and other routes. These treatments are provided to patients in various healthcare settings, including hospitals, specialty clinics, homecare, and others.

The multidrug-resistant bacteria market research report is one of a series of new reports from The Business Research Company that provides multidrug-resistant bacteria market statistics, including multidrug-resistant bacteria industry global market size, regional shares, competitors with a multidrug-resistant bacteria market share, detailed multidrug-resistant bacteria market segments, market trends and opportunities and any further data you may need to thrive in the multidrug-resistant bacteria industry. This multidrug-resistant bacteria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The multidrug resistant bacteria market size has grown strongly in recent years. It will grow from $12.61 billion in 2024 to $13.4 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to antibiotic resistance crisis, advancements in drug discovery, regulatory incentives, public health initiatives.

The multidrug resistant bacteria market size is expected to see strong growth in the next few years. It will grow to $17.5 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to antibiotic stewardship programs, global spread of resistance, phage therapy and alternative treatments, public and private investment. Major trends in the forecast period include precision medicine for infectious diseases, combination therapies, continuous surveillance and monitoring, global collaboration.

The growing prevalence of infectious diseases is expected to drive the expansion of the multidrug-resistant bacteria market. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites. Multidrug-resistant bacteria are particularly linked to infectious diseases due to their ability to cause infections that are challenging to treat with standard antibiotics. These bacteria have developed resistance to multiple antibiotics, making them less responsive to the medications typically used to treat bacterial infections. For example, in November 2023, the Centers for Disease Control and Prevention (CDC), a U.S.-based national public health agency, reported that the number of tuberculosis cases in the USA increased from 8,320 in 2022 to 9,615 in 2023, reflecting an increase of 1,295 cases. Therefore, the rising prevalence of infectious diseases is expected to fuel the growth of the multidrug-resistant bacteria market.

Major companies operating in the multidrug-resistant bacteria market are placing a strong emphasis on the development of innovative drugs and securing approvals to address the needs of a new segment of consumers. The approval of drugs designed to combat multidrug-resistant bacteria is crucial in the ongoing fight against antibiotic resistance. For example, in May 2023, Entasis Therapeutics Inc., a US-based biotech company, achieved approval from the Food and Drug Administration (FDA) for Xacduor, a combination antibiotic formulated to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VAP) caused by acinetobacter baumannii, a particularly challenging pathogen to treat. Xacduor consists of a combination of ceftolozane and tedizolid phosphate. Ceftolozane is a cephalosporin antibiotic, while tedizolid phosphate belongs to the oxazolidinone class of antibiotics. This approval provides a new treatment option for patients infected with Acinetobacter baumannii who have not responded to other therapies. It can be administered via injection and combines the antibiotic beta-lactam sulbactam with the broad-spectrum beta-lactamase inhibitor durlobactam, reducing acinetobacter resistance and enabling the antibiotic to effectively combat the infection.

In July 2022, Innoviva Inc., a US-based pharmaceutical company, acquired Entasis Therapeutics Inc. for an undisclosed amount. This strategic acquisition expands Innoviva's portfolio, encompassing potential first- and best-in-class medications for the treatment of multidrug-resistant gram-negative bacteria, including the lead asset SUL-DUR. Entasis Therapeutics Inc. is a US-based biotech company specializing in the development of antibacterial therapeutics aimed at addressing serious infections caused by multidrug-resistant bacteria.

Major players in the multidrug resistant bacteria market are Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Lupin Pharmaceuticals Inc., BioMarin Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories, Wockhardt Ltd., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Theravance Biopharma Inc., Melinta Therapeutics Inc., Armata Pharmaceuticals Inc., Tetraphase Pharmaceuticals Inc.

North America was the largest region in the multidrug-resistant bacteria market in 2024. The regions covered in multidrug-resistant bacteria report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the multidrug-resistant bacteria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multidrug-resistant bacteria market consists of revenues earned by entities by providing services such as infection diagnosis and combination therapy, surgery and antimicrobial stewardship. The market value includes the value of related goods sold by the service provider or included within the service offering. The multidrug-resistant bacteria market also consists of sales of colistin, polymyxins, aminoglycosides, antibiotic synergy kits, monoclonal antibodies and vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multidrug Resistant Bacteria Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multidrug resistant bacteria market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multidrug resistant bacteria ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multidrug resistant bacteria market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease: Urinary Tract Infection; Intra-Abdominal Infections; Blood Stream Infections; Clostridium Difficile Infections; Acute Bacterial Skin And Skin Structure Infections; Hospital Acquired Bacterial Pneumonia; Acquired Bacterial Pneumonia; Other Diseases
• 2) By Drug Class: Oxazolidinones; Lipoglycopeptides; Tetracyclines; Cephalosporins; Combination Therapies; Other Drug Classes
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Urinary Tract Infection: Cystitis; Pyelonephritis
• 2) By Intra-Abdominal Infections: Appendicitis; Peritonitis
• 3) By Blood Stream Infections: Bacteremia; Sepsis
• 4) By Clostridium Difficile Infections: Mild CDI; Severe CDI
• 5) By Acute Bacterial Skin And Skin Structure Infections: Cellulitis; Abscesses
• 6) By Hospital Acquired Bacterial Pneumonia: Ventilator-Associated Pneumonia; Hospital-Acquired Pneumonia
• 7) By Acquired Bacterial Pneumonia: Community-Acquired Pneumonia; Aspiration Pneumonia
• By Other Diseases: Bone and Joint Infections; Endocarditis
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck And Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multidrug Resistant Bacteria Market Characteristics

3. Multidrug Resistant Bacteria Market Trends And Strategies

4. Multidrug Resistant Bacteria Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Multidrug Resistant Bacteria Growth Analysis And Strategic Analysis Framework

• 5.1. Global Multidrug Resistant Bacteria PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Multidrug Resistant Bacteria Market Growth Rate Analysis
• 5.4. Global Multidrug Resistant Bacteria Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Multidrug Resistant Bacteria Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Multidrug Resistant Bacteria Total Addressable Market (TAM)

6. Multidrug Resistant Bacteria Market Segmentation

• 6.1. Global Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urinary Tract Infection
• Intra-Abdominal Infections
• Blood Stream Infections
• Clostridium Difficile Infections
• Acute Bacterial Skin And Skin Structure Infections
• Hospital Acquired Bacterial Pneumonia
• Acquired Bacterial Pneumonia
• Other Diseases
• 6.2. Global Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oxazolidinones
• Lipoglycopeptides
• Tetracyclines
• Cephalosporins
• Combination Therapies
• Other Drug Classes
• 6.3. Global Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.5. Global Multidrug Resistant Bacteria Market, Sub-Segmentation Of Urinary Tract Infection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cystitis
• Pyelonephritis
• 6.6. Global Multidrug Resistant Bacteria Market, Sub-Segmentation Of Intra-Abdominal Infections, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Appendicitis
• Peritonitis
• 6.7. Global Multidrug Resistant Bacteria Market, Sub-Segmentation Of Blood Stream Infections, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacteremia
• Sepsis
• 6.8. Global Multidrug Resistant Bacteria Market, Sub-Segmentation Of Clostridium Difficile Infections, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild CDI
• Severe CDI
• 6.9. Global Multidrug Resistant Bacteria Market, Sub-Segmentation Of Acute Bacterial Skin And Skin Structure Infections, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cellulitis
• Abscesses
• 6.10. Global Multidrug Resistant Bacteria Market, Sub-Segmentation Of Hospital Acquired Bacterial Pneumonia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ventilator-Associated Pneumonia
• Hospital-Acquired Pneumonia
• 6.11. Global Multidrug Resistant Bacteria Market, Sub-Segmentation Of Acquired Bacterial Pneumonia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Community-Acquired Pneumonia
• Aspiration Pneumonia
• 6.12. Global Multidrug Resistant Bacteria Market, Sub-Segmentation Of Other Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bone and Joint Infections
• Endocarditis

7. Multidrug Resistant Bacteria Market Regional And Country Analysis

• 7.1. Global Multidrug Resistant Bacteria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Multidrug Resistant Bacteria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multidrug Resistant Bacteria Market

• 8.1. Asia-Pacific Multidrug Resistant Bacteria Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multidrug Resistant Bacteria Market

• 9.1. China Multidrug Resistant Bacteria Market Overview
• 9.2. China Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multidrug Resistant Bacteria Market

• 10.1. India Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multidrug Resistant Bacteria Market

• 11.1. Japan Multidrug Resistant Bacteria Market Overview
• 11.2. Japan Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multidrug Resistant Bacteria Market

• 12.1. Australia Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multidrug Resistant Bacteria Market

• 13.1. Indonesia Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multidrug Resistant Bacteria Market

• 14.1. South Korea Multidrug Resistant Bacteria Market Overview
• 14.2. South Korea Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multidrug Resistant Bacteria Market

• 15.1. Western Europe Multidrug Resistant Bacteria Market Overview
• 15.2. Western Europe Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multidrug Resistant Bacteria Market

• 16.1. UK Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multidrug Resistant Bacteria Market

• 17.1. Germany Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multidrug Resistant Bacteria Market

• 18.1. France Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multidrug Resistant Bacteria Market

• 19.1. Italy Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multidrug Resistant Bacteria Market

• 20.1. Spain Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multidrug Resistant Bacteria Market

• 21.1. Eastern Europe Multidrug Resistant Bacteria Market Overview
• 21.2. Eastern Europe Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multidrug Resistant Bacteria Market

• 22.1. Russia Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multidrug Resistant Bacteria Market

• 23.1. North America Multidrug Resistant Bacteria Market Overview
• 23.2. North America Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multidrug Resistant Bacteria Market

• 24.1. USA Multidrug Resistant Bacteria Market Overview
• 24.2. USA Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multidrug Resistant Bacteria Market

• 25.1. Canada Multidrug Resistant Bacteria Market Overview
• 25.2. Canada Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multidrug Resistant Bacteria Market

• 26.1. South America Multidrug Resistant Bacteria Market Overview
• 26.2. South America Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multidrug Resistant Bacteria Market

• 27.1. Brazil Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multidrug Resistant Bacteria Market

• 28.1. Middle East Multidrug Resistant Bacteria Market Overview
• 28.2. Middle East Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multidrug Resistant Bacteria Market

• 29.1. Africa Multidrug Resistant Bacteria Market Overview
• 29.2. Africa Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multidrug Resistant Bacteria Market Competitive Landscape And Company Profiles

• 30.1. Multidrug Resistant Bacteria Market Competitive Landscape
• 30.2. Multidrug Resistant Bacteria Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson And Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Multidrug Resistant Bacteria Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca plc
• 31.5. GlaxoSmithKline plc
• 31.6. Eli Lilly and Company
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Gilead Sciences Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Mylan N.V.
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Lupin Pharmaceuticals Inc.
• 31.13. BioMarin Pharmaceuticals Inc.
• 31.14. Zydus Lifesciences Limited
• 31.15. Glenmark Pharmaceuticals Ltd.

32. Global Multidrug Resistant Bacteria Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multidrug Resistant Bacteria Market

34. Recent Developments In The Multidrug Resistant Bacteria Market

35. Multidrug Resistant Bacteria Market High Potential Countries, Segments and Strategies

• 35.1 Multidrug Resistant Bacteria Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Multidrug Resistant Bacteria Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Multidrug Resistant Bacteria Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer